IGC Pharma heads towards a Phase I study for Alzheimer’s disease
With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.
With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.
What's Your Reaction?
